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Behc ¸et’s disease (BD) is a multisystemic, relapsing inﬂammatory disorder with an obscure etiology and pathogenesis. Diagnosis
depends on the clinician’s ability to identify a group of nonspeciﬁc mucocutaneous lesions, which also manifest in a number of
otherdiseases.Inrecentyears,therehasbeenanincreaseinthestudiesfocusingonthehistopathologicalaspectsofBehc ¸et’sdisease
diagnostic mucocutaneous lesions. Their results emphasize the value of histopathology and direct immunoﬂuorescence (DIF) in
the diﬀerential diagnosis of Behc ¸et’s disease.
1.Introduction
After seventy-four years, since Dr. Hulusi Behc ¸et had pub-
lished his classic paper describing the three major signs [1],
BD are still an enigma for clinicians and researchers. Almost
all aspects of BD is a source of debate and even its diagnostic
criteria, classiﬁcation, and pathogenesis are controversial [2–
4].
In the last two decades, extensive studies have been
conducted to reveal the nature of BD. In the light of these
studies, BD is now recognized as a chronic, multisystemic
vasculitis [2, 5–7]. Whether this vasculitis is a result of
autoimmunity is controversial [2, 3], but there is increasing
evidence indicating the possible role of immunologic mech-
anisms in the pathogenesis. Evaluation of lesion-free skin
and mucocutaneous lesions of patients with BD patients by
DIF reveals immunoreactant deposits on the vessel walls [8–
11]. Also, elevated serum levels of several proinﬂammatory
cytokines (IL-1, IL-4, IL-6, TNF-α,e t c . )h a v eb e e nr e p o r t e d
in these patients [12]. A special subgroup of T lymphocytes
(γδTlymphocytes),whichplayanimportantroleinmucosal
immunity, are found to be present in the increased numbers
in circulation and mucosal lesions of patients [13]. Several
research groups found out that cultured γδ Tl y m p h o c y t e
cells proliferate when stimulated with mycobacterial heat
shock proteins and products of several oral pathogen
microorganisms [13, 14].
Correlation between the hyperactive state of neutrophils
and BD activity is another well-known fact. The underlying
mechanism is unknown. Antigen-presenting cell and T-
lymphocyte-derived cytokines and chemokines are believed
to be responsible for neutrophiles hyperreactivitiy [15].
BD is mostly encountered in the Mediterranean and
Middle and Far East countries, Turkey having the highest
prevalence with 80–420cases/100.000 [3, 16].
Genetic studies show statistically signiﬁcant association
with HLA-B51 [17, 18].
Antiendothelial antigens are another immunological
anomaly found in BD patients, but there is no solid evidence
for their participation in the pathogenesis [19].
Considering available information, it is no surprise that
most of the working hypotheses for the BD pathogenesis
point out an external factor (an infectious or regional
pathogen, i.e., Parvovirus B19 [20], Helicobacter pylori
[21], Streptococcus sanguis [22], etc.). This factor probably
stimulates an abnormal immune reaction, during which
certain types of lymphocytes are stimulated and neutrophils
reach a hyperreactive state in the people with a genetic
predisposition. Diagnosis of BD depends on the presence
of several clinical ﬁndings. These ﬁndings are deﬁned by
the International Study Group (ISG) of Behc ¸et’s Disease
and published in 1990 [23]( Table 1). Major weak points
of ISG criteria are the occasional long intervals between2 Pathology Research International
Table 1: Diagnostic criteria of Behc ¸et’s disease deﬁned by International Study Group.
Mucocutaneous lesions Description
Recurrent oral ulceration Minor, aphthous, major aphthous, or herpetiform ulceration observed by physician or patient that
recurred at least 3 times in one 12-month period
Plus 2 of the following criteria:
Recurrent genital ulceration Aphthous ulceration or scarring observed by physician or patient
Eye lesions Anterior uveitis, posterior uveitis, cells in vitreous on slit lamp examination, or retinal vasculitis
observed by ophthalmologist
Cutaneous lesions Erythema nodosum, pseudofolliculitis, papulopustular lesions, or acneiform nodules observed by
physician in postadolescent patients not receiving corticosteroid treatment
Positive pathergy test Read by physician at 24 to 48 hours
manifestations of mucocutaneous lesions with the diag-
nostic value and lack of their speciﬁcity. Similar lesions
may manifest in an extensive number of diseases (e.g.,
papulopustular lesions, erythema nodosum). Knowledge of
histopathological featuresof BDmucocutaneous lesions may
be beneﬁcial for diﬀerential and early diagnosis.
2.Aphthous OralUlcers
Aphtous oral mucosa ulcers (AOUs) are usually the initial
clinical manifestation [4, 24]. Ideguchi et al. evaluated 412
BD patients’ hospital records covering 16 years follow-up
data [4]. The result of this study revealed that in some cases
AOU had proceeded 10 years a deﬁnitive diagnosis. Unfortu-
nately, AOUs are neither speciﬁc nor rare. Similar ulcers may
be observed during the course of several systemic or local
diseases, including inﬂammatory bowel diseases (Crohn),
Sweetsyndrome,cyclicneutropenia,andherpesinfections.If
recognized by clinican, other clinicial manifestations of this
disease may enable a quick diﬀerential diagnosis.
Regardless of the concurrent disease, morphologies of
AOU are similar. An AOU has sharp borders surrounded
by an erythematous rim and a base covered with yellow-
white coloured pseudomembrane. AOUs are classiﬁed into
three groups according to ulcer diameter, but these three
morphological forms are recognized as parts of the same
spectrum.
(1) Minor aphthae are shallow mucosal ulcers with a
diameter <10mm, which may be found in groups,
usually on nonkeratinized section of oral mucosa
(lateral sides and ventral surface of tongue, mouth
ﬂoor).
(2) Major aphtous ulcers have similar morphologies, but
they have larger diameter (>10mm), are deeper than
the minor variants, and tend to heal with scarring.
(3) Herpetiform aphthae are pinpoint shaped, very small
and shallow mucosal ulcers and tend to occur in
crops. Sometimes they may converge and form large
ulcers with irregular borders.
Severalpathogeneticmechanismsforaphtousulcershave
been proposed such as T-cell-mediated immunologic reac-
tions, inhibition of mucosal healing by cytokines, nutritional
(vitamin B12, folic acid) deﬁciencies, and viral or bacterial
assault, but neither of these are proven.
To include oral aphtous ulcers in the diagnostic criteria
of BD, at minimum three episodes should be observed in
one year. Since a deﬁnitive BD diagnosis requires the other
mucocutaneous features to develop, patients may undergo a
long prediagnostic interval, manifesting only oral aphthae.
Recurrent aphtous stomatitis (RAS), the most common
type of oral aphthae [25–28], aﬀects nearly one quarter
of the world population [1] and runs a similar course
to the prediagnostic phase of BD, providing a diagnostic
challenge for the clinician. RAS patients, regardless the
intensity of the mucosal disease, do not develop any other
systemic symptoms. In recent years, many studies evaluating
morphological, histopathological, and immunohistochemi-
cal features of RAS and BD have been published [8, 25].
Oh et al. compared the clinical features of RAS and BD and
found minor diﬀerences [25]. According to this study, BD
patients tend to manifest more major aphthae on their oral
mucosa, and involvement of more than two sites was more
common in BD. Also, exacerbation of oral aphthae during
the premenstrual period was more frequent in BD patients.
But these results are not deﬁnitive for diﬀerential diagnosis,
and researchers stated that RAS patients should be followed
up for potential manifestation of BD [25].
Due to AOU tendency to spontaneous healing and well-
known morphology, biopsies are rarely performed, and,
due to similar histopathological features of all variants of
aphtous oral ulcers, histopathological examination has a
limited value in the diﬀerential diagnosis. Lymphocytes,
macrophages, and neutrophils are observed at the base of
an AOU [29]. The inﬁltrate is more pronounced around
the vessels. Although classiﬁed as vasculitis, some studies
report that most mucocutaneous lesions in BD do not
present typical characteristics of an actual vasculitis [7].
Fibrinoid necrosis in the vessel walls is reported to be very
rare [5]. At the periphery of the ulcer base, the inﬁltrate
may penetrate into the epidermis. Some recently published
direct immunoﬂuorescence (DIF) studies report IgM and C3
deposits in perivascular region with or without granular C3
deposits at the dermoepidermal junction in the perilesional
skin of AOU in Behc ¸et’s disease patients [8, 25]. Also in
another study, Wilhelmsen et al. evaluated perilesional skin
of 23 RAS patients with direct immunoﬂourescence andPathology Research International 3
Table 2: An overview of the reported histopathological and immunoﬂourescence features of Behc ¸et’s disease common mucocutaneous
lesions.
Mucocutaneous lesions Reported histopathological features
Recurrent oral Aphthae
Lymphocytes, macrophages, neutrophils at the base of the ulcer, sometimes penetrating epidermis at
the periphery
Similar inﬁltrate at the perivascular regions in dermis ﬁbrinoid necrosis of vessel walls (rare)
Also granular IgM and C3 deposits in dermoepidermal junction and in perivascular regions (in RAS,
no deposits of immunoreactants) [30]
Genital ulceration Similar histopathological features to oral aphthae
Erythema-nodosum-like lesions
Neutrophilic vasculitis
Lymphocytic vasculitis
Necrobiosis
IgM deposits at the vessel walls [40]
Pathergy reaction
Perivascular inﬁltrate of mononuclear cells
Vasculitis (neutrophilic, leukocytokclastic) (+/−)
Presence of mast Cells.
IgM, IgA, and C3 deposits
Papulopustular lesions
Intraepidermal pustules, spongiosis, neutrophil/lymphocyte exocytosis, and basal keratinocyte
vacuolization,
Edema in dermis, lymphohistiocytic/neutrophilic inﬂammatory inﬁltration between collagen ﬁbers,
and perivascular areas
Vasculitis (+/−)
Thrombophlebitis Thrombi in the vessel lumen
Perivascular inﬁltrate of mononuclear cells
found out the immunocomplexes to be absent [30]. Clinical
signiﬁcance of this study requires to be validated by other
studies. If validated, this ﬁnding may be of utmost value in
the diﬀerential diagnosis of RAS and BD (see Table 2).
3. GenitalUlcers
Genital ulcers manifest in the majority of BD patients
[31, 32]. Usually larger than oral aphthae, genital ulcers
of BD have similar clinical features. Most common places
for genital ulceration are the scrotum and the shaft of the
penis in men and the major and minor labia in women.
Genital ulcers have irregular borders, are deeper than oral
aphthae, and heal with scarring and occasionally causing
ﬁstulae extending to the urethra or bladder. Borders of
genital ulcers are surrounded by an erythematous rim and
ﬁbrinous material, and whitish-yellow pseudomembranes
can be found on the ulcer base. Observation of genital ulcers
or remaining scars is of diagnostic value.
Many sexually transmitted diseases (STDs) manifest
with genital ulcers, but usually, most STD diagnoses can
easily be established with physical examination ﬁndings
(i.e., lymphadenopathies—bubo formation in chancroid,
lack of pain in syphilitic ulcer fever, and malaise). Also,
direct observation of pathogenic microorganisms obtained
via swaps by Wright, Giemsa stains and cultures for the
suspected pathogens from ulcer bases usually make the
histopathological evaluation inessential. Histopathology of
genital ulcers is similar to that of the oral aphthae. The same
mixed inﬁltrate consisting of neutrophiles, lymphocytes, and
macrophages is ever-present at the ulcer base. In conclusion,
diagnosis of Behc ¸et’s disease genital ulcers is a diagnosis of
exclusion (see Table 2).
4.ExtragenitalUlcers
In some BD patients, cutaneous ulcerations similar to
aphtous lesions are reported on diﬀerent locations other
than oral mucosa and external genitalia. Legs, neck [33], and
interdigital areas are some of the reported sites. Extragenital
ulcers are seen in about 3% of BD patients and observed
usually in children [34, 35]. A typical extragenital ulcer is a
small,circumscribed,shallowulcerwitharedrimandyellow
or grey base. These ulcers may persist for weeks and can be
very painful. Due to their infrequency, there are few case
reports and fewer studies evaluating these ulcers. Azizlerli et
al. reported vasculitis in four cases [33] (see Table 2).
5. Erythema-Nodosum-Like Lesions
Nodular lesions located on the lower extremities resembling
erythema nodosum are frequently seen in Behc ¸et’s disease
patients. Erythema-nodosum-like lesions (ENLs) are rather
common [36]. ENLs manifest mostly in females. Other
than lower extremities, ENLs are reported on face and neck
[31]. ENLs do not ulcerate and heal in 2-3 weeks. The
main diﬀerence between erythema nodosum and ENL is the
existence of vasculitis and necrobiosis in the latter. Nodular
vasculitis is another condition, which may resemble ENL4 Pathology Research International
and can be distinguished by the presence of granulomas and
lymphocytic inﬁltration of subcutis.
There are conﬂicting results concerning the nature of
the vasculitis. Two research groups, Chun et al. [37]a n d
Kim and LeBoit [38], reported “lymphocytic vasculitis” as
the dominant pattern. On the other hand, observation of
“neutrophilic vasculitis” patterns was also reported [4, 39].
PathogenesisofENLvasculitisisunknown.Kanekoetal.[40]
reported IgM deposits in the vessel walls in the lesional skin.
Some authors believe this vasculitis to be a secondary event
to lymphocytic inﬁltration [37]; others [41] proposed ENL
vasculitis as a primary vasculitis (see Table 2).
6. Pathergy Reaction
The term “pathergy” is used to deﬁne the cutaneous hyper-
reactivity to minimal trauma. A positive pathergy reaction in
BD is characterized by an erythematous, indurated papule
at the site of trauma, which usually evolves into a sterile
pustule. Pathergy is one of the diagnostic criteria for BD
and accepted as a sign for the active disease. Neutrophilic
dermatoses (pyoderma gangrenosum, Sweet syndrome, and
erythema elevatum diutinum) are also known for positive
pathergy reaction. In this conditions, especially in pyoderma
gangrenosum (PG), positive pathergy may have diﬀerent
manifestations. Pathergy in PG may describe development
of the new skin lesions, the exacerbation of the existing
ones following a minor skin trauma, or rapid enlargement
of PG after debridement [42, 43]. Pathergy positivity is also
reported in chronic myeloid leukemia (CML) patients [42].
The underlying mechanism of pathergy is unknown, and
test positivity diﬀers between diﬀerent countries. Pathergy
positivity is observed more frequently in the Mediterranean
peninsula and Japan [31].
Results of the histopathological studies of pathergy in
BD are conﬂicting. The only consensus on this subject is
the presence of an inﬁltrate consisting of mononuclear cells
around dermal vessels at the pathergy site. Some studies
revealed the neutrophils as the major constituent of the
inﬁltrate [44], while research groups found percentage of
neutrophils relatively low [45]. There are also conﬂicting
results in regard to vasculitis in pathergy of BD. Jorizzo et al.
reported leukocytoclastic vasculitis [46]. Ergun et al. studied
the change in the histopathological features of pathergy in
BD patients and failed to observe a vasculitic pattern [47].
Presence of mast cells at the pathergy site is another
histopathological feature worth of mentioning [42, 48].
Degranulation of mast cells is suggested to play a role in the
pathergy [42, 49].
In2009,KosepublishedapaperevaluatingIgG,IgM,IgA,
andC3 depositsin108BDpatientsbydirectimmunoﬂoures-
cence, 44 of the skin samples were obtained from positive
pathergy sites, and high deposition rates of IgM, IgA,
and C3 were found [8], indicating a probable underlying
autoimmune mechanism (see Table 2).
7. PapulopustularLesions (PPLs)
Papulopustular lesions (PPLs) are the most common cuta-
neous manifestation of BD [31, 32]. PPLs are observed on
thetrunk,face,andextremities.ISGcriteriaconcerningPPLs
deﬁne them as “pseudofolliculitis or papulopustular lesions;
or acneiform nodules observed by physician in postado-
lescent patients not receiving corticosteroid treatment” and
do not clarify the exact nature of lesions. ISG deﬁnition
of PPL refers to papular lesions on an erythematous base
and progressing to sterile pustules [50], but papulopustular
lesions of acne are also consistent with this deﬁnition,
renderingthiscriteriaimpracticalintheBDdiagnosisduring
the adolescence period.
Todeterminewhetherapapulopustulareruptionisapart
of BD complex is probably the most challenging part of the
diagnostic process. Some authors propose that nonfollicular
lesions located in other than face are more speciﬁc for
Behc ¸et’s disease [31] and some propose exclusion of PPL
from the diagnostic criteria due to its vague deﬁnition [50].
Despite the increasing number of studies evaluating the
histopathological features of PPL, the exact nature of PPL is
still needed to be established.
The results of these histopathological studies are also
contradictory. Certain study results indicate the presence of
vasculitis [5, 31, 32, 50] in the histopathological sections and
suggest that the term “pseudofolliculitis” is a misnomer and
that it should be dropped [5, 31], while some authors report
perifolliculitis or suppurative folliculitis observed during the
histopathological evaluations and consider histopathological
sections of little help in the diﬀerential diagnosis [51]. More
recentstudiessupporttheroleofvasculitisintheevolutionof
Behc ¸et’s disease papulopustular lesions [5, 10, 31]. Intraepi-
dermal pustules, spongiosis, neutrophil or lymphocyte exo-
cytosis, basal keratinocyte vacuolization, edema in dermis,
lymphohistiocytic or neutrophilic inﬂammatory inﬁltration
between collagen ﬁbers and perivascular areas, ﬁbrin deposi-
tionwithinvesselwalls,endothelialswelling,anderythrocyte
extravasation are reported as the histopathological features
of Behc ¸et’s disease PPL [10]. To further clarify the presence
of vasculitis, PPLs were evaluated by immunoﬂuorescence
[8, 9, 11]. A study by ˙ Ilknur et al. failed to ﬁnd any
diﬀerence between the direct immunoﬂuorescence ﬁndings
of eighteen Behc ¸et’s disease patients and sixteen patients
with bacterial folliculitis and ﬁve patients with acne [9]. In
other two studies [8, 11] (seventeen and one hundred eight
patients, resp.) immunoreactant deposition in the lesional
and nonlesional skin of the BD patients was evaluated and
signiﬁcant deposition, especially IgM in the lesional skin
was reported, supporting the immune-mediated vasculitis
hypothesis (see Table 2).
8.Thrombophlebitis
Behc ¸et’s disease may also aﬀect major vessels. Although there
are conﬂicting views about the presence of an actual vas-
culitis in the mucocutaneous lesions of BD, actual vasculitis
of major vessels is welldocumented [7, 31]. Involvement of
any vessel is possible, but venous system seems to be thePathology Research International 5
primary target [52, 53] and subcutaneous thrombophlebitis
isreportedtobethemostfrequentinthevenousinvolvement
[31]. Exact pathogenesis is unknown, but Th-1 type inﬂam-
matory response is suspected just as in other vasculitides
like Wegener Granulomatosis and temporal arteritis. Unlike
other primary vasculitides, major vascular involvement of
BD predominantly aﬀects males [7].
Subcutaneous thrombophlebitis is another common
cutaneous manifestation of BD. Erythematous, tender nod-
ules occur on the site of venous involvement. Consistent
with the size of the aﬀected vessel, an erythematous, lineer
hardening can also be palpated. During an activation period,
several separate nodules may manifest consecutively on
diﬀerent localizations since multiple vascular segments may
be involved, so BD must always be included in the diﬀer-
ential diagnosis of “superﬁcial migratory thrombophlebitis.”
Superﬁcial thrombophlebitis may also herald the coexisting
major vessel vasculitis and thrombotic condition [54, 55].
Histopathology of superﬁcial thrombophlebitis is nonspe-
ciﬁc. A thrombi in the vascular lumen and concomitant
perivascular inﬁltrate consisting of mononuclear cells are the
classical histopathological features (see Table 2).
9.RareCutaneousLesions
There is an increasing number of reports about other
coexistent cutaneous lesions in Behc ¸et’s disease patients.
Among these are; erythema-multiforme-like lesions [56],
polyarteritis nodosa-like lesions [57], pernio-like lesions
[58], Sweet syndrome [59], necrotizing folliculitis [60], and
necrotizing cutaneous small vessel vasculitis. Since reports of
similar cases are so rare, association between BD and these
skin lesions is not clear and they can be coincidental [31]. No
extraordinary histopathological ﬁndings in these cases were
reported.
Abnormalities observed in nailfold capillaroscopy are
an intriguing and recently deﬁned aspect of BD. Unlike
the aforementioned cutaneous lesions, abnormalities in the
periungual vessels were observed in relatively large patient
populations. Movasat et al. described enlarged capillaries
(26%), hemorrhages (16%) in the nail folds of 128 patients
with BD [61], and suggested high blood pressure due to
Behc ¸et’s disease major vessel involvement as the probable
underlying factor.
10. Conclusion
Diagnosis of BD still depends of the clinican’s ability to rec-
ognize various, nonspeciﬁc mucocutaneous lesions and this
nonspeciﬁccharacteroflesionsmaybeamajorproblemdur-
ing the diagnostic process (e.g., whether the papulopustular
lesions of a patient with recurrent AOU belong to diagnostic
criteria). In recent years, histopathological and immuno-
histochemical evaluation of BD mucocutaneous lesions of
B has become focus of many research groups, aiming to
enhance the diagnostic value of these lesions. Although there
are some contradictory reports, there are increasing reports
supporting an underlying immune-mediated vasculitis in
the BD mucocutaneous lesions. Leukocytoclastic vasculitis,
ﬁbrinoid necrosis of postcapillary venules, or perivascular
neutrophilic accumulations are some of the reported pat-
terns in the early stages of the cutaneous lesions [31]. In
conclusion, for the diﬀerential diagnosis of mucocutaneous
lesions of BD (e.g., recurrent oral aphthae, papulopustular
eruptions), immunoﬂourescence methods seem promising.
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